Phase 1 study to evaluate safety and pharmacokinetic property of DNP001 in patients with JL1 postive acute leukemia or myelodysplastic syndrome
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Leukotuximab (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors 3SBio
- 21 Dec 2017 Status changed from recruiting to completed.
- 06 Oct 2014 New trial record
- 07 Aug 2014 This trial was initiated in June 2014 and is expected to be completed in late 2015, according to a 3SBio media release.